Indicator Four: Number TBD TBD TBD 270 Annual M&E System/ % of supported firms that Supported firms maintained calls, maintained and/or and/or increased the wages of increased the wages of their employees and their employees interviews compared to the situation before BRAVE. Baseline and annual targets to be defined after completion of baseline study. Indicator Five: Number TBD 500 1500 2500 Annual M&E System/ SMEPS # Number of Patients Patients consultations provided Phone calls, consultations provided by the supported health by the health providers providers and that have benefitted interviews from BRABE support Indicator Six: Number 0 0 15 40 Annual M&E System/ SMEPS # Number of the Supported lead firms that have Phone calls, supported lead firms that introduced new products and/or have introduced new new markets channels and products and/or new interviews markets channels as a result of BRAVE initiative Number 70 70 100 150 Annual M&E System/ SMEPS Percentage of supported Indicator Seven: Supported firms have access to Phone calls, that have access to finance from Banks at the end of finance from partners the program and Banks at the end of the interviews program. Baseline is based on 27%market average. To be revised after completion of baseline study. Indicator Eight: Percent N.A TBD (as 15 20 Annual Average increase of BAs’ (baseline baseline) Revenues from service fees 2017) Indicator Nine: Percent N.A TBD (as 15 20 Annual Average increase of BAs’ (baseline baseline) Membership 2017) Indicator Ten: Percent N.A TBD (as 20 30 Annual Average increase in Domestic (baseline baseline) Purchases from Lead firms 2017) supported by BRAVE increase their (Supplier Benefit) Indicator Eleven: Percent N.A TBD (as 50 75 Annual (baseline baseline) 2017)
Indicator Four: Supported firms maintained and/or increased the wages of their employees Number TBD TBD TBD 270 Annual M&E System/ calls, and interviews % of supported firms that maintained and/or increased the wages of their employees compared to the situation before BRAVE. Baseline and annual targets to be defined after completion of baseline study. Indicator Five: Patients consultations provided by the supported health providers Number TBD 500 1500 2500 Annual M&E System/ Phone calls, and interviews SMEPS # Number of Patients consultations provided by the health providers that have benefitted from BRABE support Indicator Six: Supported lead firms that have introduced new products and/or new markets channels Number 0 0 15 40 Annual M&E System/ Phone calls, and interviews SMEPS # Number of the supported lead firms that have introduced new products and/or new markets channels as a result of BRAVE initiative Indicator Seven: Supported firms have access to finance from Banks at the end of the program Number 70 70 100 150 Annual M&E System/ Phone calls, and interviews SMEPS Percentage of supported that have access to finance from partners Banks at the end of the program. Baseline is based on 27%market average. To be revised after completion of baseline study. Indicator Eight: Average increase of BAs’ Revenues from service fees Percent N.A (baseline 2017) TBD (as baseline) 15 20 Annual Indicator Nine: Average increase of BAs’ Membership Percent N.A (baseline 2017) TBD (as baseline) 15 20 Annual Indicator Ten: Average increase in Domestic Purchases from Lead firms supported by BRAVE increase their (Supplier Benefit) Percent N.A (baseline 2017) TBD (as baseline) 20 30 Annual Indicator Eleven: Percent N.A (baseline 2017) TBD (as baseline) 50 75 Annual